Lilly's Portrazza: Box Warning + Modest Efficacy Could Still = Sales Success
Executive Summary
EGFR inhibitor necitumumab may find place in first-line squamous type non-small cell lung cancer market due to limited treatment options – at least for now.
You may also be interested in...
Lilly's Necitumumab: FDA Panel To Weigh Modest Survival Benefit Against Thromboembolic Risks
Is benefit/risk profile in squamous non-small cell lung cancer impacted by Phase III results from trial in non-squamous population that was halted early due to safety issues?
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.